Theriva reports Q3 2023 cash of $31.2M, VCN-01 trial on track for H1 2024 enrollment completion

Theriva Biologics, Inc.

2023-Q3 EPS reported -$0.81

Cash and equivalents $31.2M as of Sept 30, 2023; expected runway into Q1 2025.
R&D expense $4.0M in Q3 2023, up 56% from $2.6M YoY, driven by VCN-01 clinical costs.
VIRAGE Phase 2b trial of VCN-01 in metastatic PDAC remains on track to complete enrollment in H1 2024.
Meeting with FDA before year-end to discuss VCN-01 development pathway for pediatric retinoblastoma.
SYN-004 Phase 1b/2a trial in HCT recipients on track for second cohort enrollment in H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theriva Biologics, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116754

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.